Combined TRAF6 Targeting and Proteasome Blockade Has Anti-myeloma and Anti-Bone Resorptive Effects - Chen, Haiming; Li, Mingjie; Sanchez, Eric; Wang, Cathy S.; Lee, Tiffany; Soof, Camilia M.; Casas, Christian E.; Cao, Jasmin; Xie, Colin; Udd, Kyle A.; DeCorso, Kevin; Tang, George Y.; et al. (Molecular cancer research, 2017)
Keywords: Activation; Apoptosis; Biocompatibility; Biomedical materials; Bone loss; Bone marrow; Bone resorption; Bortezomib; Bortezomib - pharmacology; Cancer; CD14 antigen; Cell Line, Tumor; Cell Proliferation - drug effects; Cell Survival - drug effects; Dentin; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic - drug effects; Humans; I-kappa B Kinase - metabolism; Interleukin 1; Interleukin 1 receptors; JNK protein; Leukocytes (mononuclear); Monoclonal gammopathy; Monoclonal Gammopathy of Undetermined Significance - genetics; Monoclonal Gammopathy of Undetermined Significance - metabolism; Monocytes; Multiple myeloma; Multiple Myeloma - genetics; Multiple Myeloma - metabolism; NF-κB protein; Oligopeptides - pharmacology; Patients; Peptides; Peptides - pharmacology; Proteasome inhibitors; Remission; Signal transduction; Signal Transduction - drug effects; Signaling; TNF Receptor-Associated Factor 6 - antagonists & inhibitors; TNF Receptor-Associated Factor 6 - genetics; TNF Receptor-Associated Factor 6 - metabolism; TRAF6 protein; TRANCE protein; Tumor cells; Tumor necrosis factor; Tumor necrosis factor receptors; Ubiquitination - drug effects; Up-Regulation